Antiviral Drug
As older Americans continue to shoulder COVID-19 burden, treatments are underutilized
As older Americans continue to shoulder much of the COVID-19 burden, new data show that most went without a vaccine last winter and that those who got sick rarely received antivirals.
Molnupiravir cuts risk for severe COVID-19 symptoms — and possibly long COVID
The antiviral molnupiravir modestly reduces the risk for severe symptoms of COVID-19 and may also reduce the risk for long COVID, according to a randomized controlled trial.
Paxlovid, Lagevrio reduce mortality risk in patients with COVID-19
As an outpatient treatment for COVID-19, the antivirals Paxlovid and Lagevrio were both associated with reduced mortality rates, but only Paxlovid was associated with a reduction in hospitalization, data show.
FDA revises EUA for Paxlovid, allowing pharmacists to prescribe it
The FDA announced that state-licensed pharmacists can now prescribe the COVID-19 treatment Paxlovid with some limitations.
WHO recommends Paxlovid for patients with non-severe COVID-19
WHO has announced that it strongly recommends administering Pfizer’s Paxlovid to patients with non-severe COVID-19 who are at highest risk for hospitalization.
These steps may identify patients eligible for shorter DAA therapy
Measuring hepatitis C virus at baseline and on days 7 and 14 of therapy — and eliminating blood draws on days 2 and 28 — can identify patients who may be eligible for a shorter duration of therapy, according to a study.
Antiviral reduces risk for hospitalization, death by about 50% in patients with COVID-19
Molnupiravir, an investigational oral antiviral drug, significantly reduced the risk for hospitalization or death from COVID-19 among high-risk patients, according to a company press release.